Triazine Compounds for G2/M Phase Blockade in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer agents used in chemotherapy often rely on stabilizing tubulin polymerization, which can lead to resistance in cancer cells, and there is a need for agents that act through different mechanisms to effectively treat cancers like colon, lung, and breast cancer.
Innovation Solution
Development of a class of triazine compounds that act as cytostatic and cytotoxic agents by blocking the cell cycle at the G2/M phase without significantly stabilizing tubulin polymerization, offering an alternative mechanism of action compared to traditional taxanes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional taxanes are used to stabilize tubulin polymerization, then anti-cancer efficacy is improved, but cancer cell resistance develops and tubulin polymerization is excessively stabilized
Solution Approach 1:
The patent changes the mechanism parameter from tubulin stabilization to cell cycle phase blocking. The triazine compounds block cancer cells at the G2/M phase transition without significantly stabilizing tubulin polymerization, thereby maintaining anti-cancer efficacy while avoiding the resistance problem associated with excessive tubulin stabilization
Solution Approach 2:
The patent introduces triazine compounds as an intermediary mechanism between traditional tubulin stabilizers and cancer cell death. These compounds act through cell cycle blockade at G2/M phase, serving as an alternative pathway that achieves anti-cancer efficacy without the harmful side effect of inducing cancer cell resistance through excessive tubulin stabilization
2Reliability
If traditional taxanes are used to treat cancer, then tumor growth is inhibited, but the mechanism is not diverse enough to overcome resistance
Solution Approach 1:
The patent changes the mechanism parameter from tubulin polymerization stabilization to cell cycle phase blocking. By targeting a different biological parameter (cell cycle regulation vs. cytoskeletal stability), the triazine compounds provide mechanism diversity that enables effective treatment of cancers resistant to traditional taxanes while maintaining tumor growth inhibition
3Reliability
If triazine compounds block cell cycle at G2/M phase without stabilizing tubulin, then cancer cell proliferation is inhibited with minimal resistance, but the mechanism differs from traditional effective treatments
Solution Approach 1:
The patent changes the mechanism parameter to cell cycle phase blocking at G2/M transition. This parameter change achieves reliable anti-cancer efficacy with minimal resistance development, as the mechanism differs from traditional tubulin-stabilizing agents, thereby avoiding cross-resistance while maintaining therapeutic effectiveness
Data Source
AI summary
The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.